# AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

> **NCT05239221** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Chronic Hypoparathyroidism

## Interventions

- **DRUG:** AZP-3601
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05239221
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-07
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239221, "AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05239221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*